• KOL
    • breast cancer
    • Jean M Levêque

      Jean M Levêque

      Service de Gynécologie, Hôpital Sud, Centre Hospitalo - Universitaire de Rennes, Rennes, France | CHU Rennes, Rennes, France | Gynecology Department of Rennes Teaching ...

       

       

      KOL Resume for Jean M Levêque

      Year
      2022

      Service de Gynécologie, Hôpital Sud, Centre Hospitalo - Universitaire de Rennes, Rennes, France

      2021

      Department of Obstetrics and Gynecology, Rennes University Hospital, CHU Hôpital Sud, 16 Bd de Bulgarie, Rennes Cedex 2 35 200, France.

      2020

      Département de Gynécologie Obstétrique et Reproduction Humaine, 16, boulevard de Bulgarie, 35000 Rennes, France; CHU Anne de Bretagne, UFR Médecine Université de Rennes 1, 35000 Rennes, Bretagne, France.

      Department of Gynecology, Rennes University Hospital, 35000 Rennes, France;, (L.D.);, (K.N.T.);, (J.L.)

      Faculté de médecine, Université de Rennes 1, 35000 Rennes, France;,

      IRSET, Equipe 8, INSERM University 1085, 35000 Rennes, France

      2019

      Faculty of Medicine, University of Rennes

      Departments of, Gynecology, Obstetrics and Reproductive Medicine

      Commission de cancérologie du college national des gynecologues obstetriciens français (CNGOF), 75002 Paris, France

      2018

      Service de Gynécologie, CHU de Rennes, Hôpital sud, 16 Bd de Bulgarie, 35000, Rennes, France

      2017

      Département de gynécologie obstétrique et reproduction humaine, centre hospitalier universitaire de Rennes, 16, boulevard de Bulgarie, BP 90347, 35203 Rennes cedex 2, France

      2016

      Departement of Gynecological Surgery, Rennes University Hospital, Rennes, France.

      Department of Gynecology, Obstetrics and Human Reproduction, University Hospital, Rennes, France Comprehensive Cancer Center Eugene Marquis, Rennes, France

      2015

      Surgical Department, CHU Rennes Sud, Rennes, France

      2014

      Department of Gynecology, CHU Anne de Bretagne, Rennes, Brittany, France

      Team Death Receptors and Tumor Escape, Inserm U1085;

      Faculty of Medicine, Rennes University;

       

       

      Jean M Levêque: Influence Statistics

      Sample of concepts for which Jean M Levêque is among the top experts in the world.
      Concept World rank
      precursor breast cancer #1
      zoledronate data #1
      recommended surgical staging #1
      factors residual #1
      bicyclists vulva #1
      israsm #1
      272kg #1
      pregnancy introductionthe aim #1
      prophylactic surgery tamoxifene #1
      detectable cd40 levels #1
      neoplasia cesarean #1
      rate historical cohort #1
      management pregnancy loss #1
      invasive carcinoma cnb #1
      medline baseline interrogation #1
      raloxifene tamoxifene #1
      ovca cultures #1
      early miscarriage management #1
      deepidermalized transverse #1
      prostheses filled implants #1
      papsmear 25 #1
      twentysix factors #1
      adhesion french obstetricians #1
      mastectomy hormonal deprivation #1
      contraceptive profile #1
      presence fea #1
      fea cnb #1
      osna techniques #1
      women younger counterparts #1
      colposcopic exploration #1
      prévention cancers #1
      skin recurrence #1
      aeh precursor #1
      patients pathological papsmears #1
      online vignettebased study #1
      upper twothird #1
      production ovca #1
      iosnti breast #1
      45 years p005 #1
      1244 fcu #1
      tamoxifene raloxifene #1
      iosnti #1
      isolated skin recurrence #1
      mastectomy israsm #1

       

      Prominent publications by Jean M Levêque

      KOL-Index: 13950

      BACKGROUND: The orphan receptors COUP-TF (chicken ovalbumin upstream promoter transcription factor) I and II are members of the nuclear receptor superfamily that play distinct and critical roles in vertebrate organogenesis. The involvement of COUP-TFs in cancer development has recently been suggested by several studies but remains poorly understood.

      METHODS: MCF-7 breast cancer cells overexpressing COUP-TFI and human breast tumors were used to investigate the role of COUP-TFI in the ...

      Known for Cxcr4 Expression | Breast Cancer | Cell Migration | Coup Tfi | Nuclear Receptor
      KOL-Index: 10771

      Flat epithelial atypia (FEA) is recognized as a precursor of breast cancer and its management (surgical excision or intensive follow-up) remains unclear after diagnosis on core needle biopsy (CNB). The aim of this study was to determine the underestimation rate of pure FEA on CNB and clinical, radiological, and pathological factors of underestimation. 4,062 CNBs from 5 breast cancer centers, performed over a 5-year period, were evaluated. A CNB diagnosis of pure FEA was made in 60 cases ...

      Known for Surgical Excision | Core Needle Biopsy | Fea Cnb | Epithelial Atypia | Pure Flat
      KOL-Index: 10509

      OBJECTIVE: Vulvar intraepithelial neoplasia (VIN) and vulvar Paget disease are managed with either vulvectomy, destructive treatments (laser, antimitotic drugs) or immunostimulants. All these options are associated with functional complications. The purpose of this study was to evaluate the surgical technique consisting of skinning vulvectomy with split-thickness skin graft, and its effect on overall quality of life and sexual function.

      METHODS: A retrospective study was conducted on ...

      Known for Paget Disease | Sexual Function | Vulvar Intraepithelial Neoplasia | Quality Life | Patients Vin
      KOL-Index: 10248

      BackgroundLittle data exist about the clinical management and survival of elderly patients with endometrial cancer. This study aimed to evaluate the management of elderly and very elderly patients with endometrial cancer as well as the overall survival (OS) rate, disease-free survival (DFS) rate, and cancer-specific survival (CSS) rate in a multicenter cohort.MethodsData from 1228 patients with endometrial cancer who received primary treatment between January 2001 and December 2012 were ...

      Known for Elderly Patients | Endometrial Cancer | 80 Years | Management Survival | Pelvic Lymphadenectomy
      KOL-Index: 9977

      AIMS: To determine factors predictive of the presence of residual tumor on the specimen from mastectomy performed after conservative treatment for breast cancer in order to limit potentially unnecessary mastectomies (free of residual lesions).

      MATERIALS AND METHODS: 294 patients treated in 2 expert centers for breast cancer with breast-conserving therapy (BCT) followed by mastectomy, according to French recommendations, were investigated between January 1, 1998 and January 1, 2005. ...

      Known for Residual Tumor | Breast Cancer | Positive Margins | Predictive Factors | Neoplasms Carcinoma
      KOL-Index: 9928

      PURPOSE: Several models have been developed to predict nonsentinel lymph node (non-SN) status in patients with breast cancer with sentinel lymph node (SN) metastasis. The purpose of our investigation was to compare available models in a prospective, multicenter study.

      PATIENTS AND METHODS: In a cohort of 561 positive-SN patients who underwent axillary lymph node dissection, we evaluated the areas under the receiver operating characteristic curves (AUCs), calibration, rates of false ...

      Known for Lymph Node | Breast Cancer | Subgroup Patients | Prospective Multicenter Study | Metastatic Sentinel
      KOL-Index: 9427

      Lobular neoplasia (LN) is a risk factor for bilateral breast cancer without consensus as to its appropriate management. The authors report on a retrospective multi-institutional study concerning 52 patients in whom a diagnosis of LN was made after core needle biopsy (CNB) and who subsequently underwent surgical excision. The excision specimens revealed seven cases of invasive carcinoma and three cases of ductal carcinoma in situ, indicating an underestimation of lesions at CNB in 19% of ...

      Known for Core Needle Biopsy | Surgical Excision | Lobular Neoplasia | Noninfiltrating Carcinoma | Needle Breast
      KOL-Index: 9338

      PURPOSE: To determine the detection rate, the false-negative rate, and the accuracy of sentinel lymph node (SLN) detection after neoadjuvant chemotherapy (NAC) for advanced breast cancer.

      PATIENTS AND METHODS: A prospective multicentric study was initiated to evaluate the results of SLN biopsy with the combined method after NAC for advanced large operable breast cancer.

      RESULTS: From September 2003 to March 2007, 195 patients enrolled from 12 institutions were found suitable for ...

      Known for Node Biopsy | Neoadjuvant Chemotherapy | Sentinel Lymph | Detection Rate | Advanced Breast
      KOL-Index: 8816

      OBJECTIVE: This study aims to evaluate the different surgical approaches, perioperative morbidity and surgical staging according to age in patients with endometrial cancer.

      METHODS: Multicentre retrospective study. Cancer characteristics and perioperative data were collected for patients surgically treated for endometrial cancer. The patients were divided into 2 groups according to their age: younger or older than 75 years.

      RESULTS: Surgery was performed on 270 women <75 years old and on ...

      Known for Endometrial Cancer | Robotic Surgery | Surgical Staging | Lymph Node Excision | Younger Women
      KOL-Index: 8191

      BackgroundThe European Society of Medical Oncology (ESMO)/European Society of Gynaecological Oncology (ESGO)/European Society for Radiotherapy & Oncology (ESTRO) classification for endometrial cancer (EC) now includes a high–intermediate risk (HIR) group of recurrence due to the adverse prognostic role of lymphovascular space involvement (LVSI) and grade 3 for women at intermediate risk. However, optimal surgical staging, and especially the place of lymphadenectomy, remains to be ...

      Known for Intermediate Risk | Nodal Staging | Endometrial Cancer | Lymph Node | Aged Neoplasm
      KOL-Index: 8100

      One-step nucleic acid amplification (OSNA, Sysmex, Kobe, Japan) offers an excellent opportunity for accurate exhaustive sentinel lymph node (SLN) examination in breast cancer patients. Calibrated with conventional postoperative histology, this molecular technique yields comparable results intraoperatively, expressed as micrometastasis, macrometastasis or no metastasis depending on the CK19 mRNA copy number amplified in SLN lysates. We applied OSNA to detect metastasis in 810 SLNs from ...

      Known for Breast Cancer | Sentinel Lymph | Acid Amplification | Osna Assay | Intraoperative Detection
      KOL-Index: 7836

      INTRODUCTION: Dendritic cells (DCs) are antigen-presenting cells that are currently employed in cancer clinical trials. However, it is not clear whether their ability to induce tumour-specific immune responses when they are isolated from cancer patients is reduced relative to their ability in vivo. We determined the phenotype and functional activity of DCs from cancer patients and investigated the effect of putrescine, a polyamine molecule that is released in large amounts by cancer ...

      Known for Breast Cancer | Dendritic Cells | Cell Carcinoma | Activity Lymphocytes | Retinoic Acid
      KOL-Index: 7460

      BACKGROUND: Concomitant chemoradiation (CRT) (including brachytherapy) is considered the standard management for stage IB2 or II cervical cancer in many countries. Nevertheless, some of them discuss completion surgery (hysterectomy [HT]) after CRT. The aim of this study was to investigate the therapeutic impact of such surgery.

      METHODS: A randomized trial was opened in France in 2003 to evaluate the interest in HT after CRT. Inclusion criteria were: (a) stage IB2 or II cervical cancer ...

      Known for Stage Ib2 | Complete Response | Chemoradiation Therapy | Cervical Cancer | Completion Surgery
      KOL-Index: 7448

      The incidence (rate per 100 000) of borderline ovarian tumors (BOTs) increases progressively with age, starting at 15-19 years and peaking at around 4.5 cases per 100 000 at an age of 55-59 years (LE3) with a median age of 46 years. The five year survival for FIGO stages I, II, III and IV is 99.7 % (95 % CI: 96.2-100 %), 99.6 % (95 % CI: 92.6-100 %), 95.3 % (95 % CI: 91.8-97.4 %) and 77.1 % (95 % CI: 58.0-88.3 %), respectively (LE3). An epidemiological association exists between the ...

      Known for Grade Case | Ovarian Tumors | Mri Recommended | Recurrence Bot | Peritoneal Implants

      Key People For Breast Cancer

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Gabriel N Hortobagyi
      breast cancer neoadjuvant chemotherapy estrogen receptors
      #3
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #4
      Charles M Perou
      breast cancer gene expression intrinsic subtypes
      #5
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      #6
      Jacques Ferlay
      cancer incidence global burden latin america

      Jean M Levêque:Expert Impact

      Concepts for whichJean M Levêquehas direct influence:Breast cancer,  Residual tumor,  Endometrial cancer,  Elderly patients,  Ovarian cancer,  Fecal incontinence,  Vγ9vδ2 cells,  Elderly women.

      Jean M Levêque:KOL impact

      Concepts related to the work of other authors for whichfor which Jean M Levêque has influence:Breast cancer,  Neoadjuvant chemotherapy,  Lymph node,  Therapeutic vaccines,  Uterus transplantation,  Flat epithelial atypia,  Human papillomavirus.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Service de Gynécologie, Hôpital Sud, Centre Hospitalo - Universitaire de Rennes, Rennes, France | CHU Rennes, Rennes, France | Gynecology Department of Rennes Teaching Hospital, Service de Gynécologie du CHU de Rennes, Hôpital sud 16 Bd de Bulgarie,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.